Outlook Therapeutics 正式宣布，其药物 Lytenava™ 已获得美国食品药品监督管理局（FDA）批准。这是首款、也是唯一一款获 FDA 许可、专用于治疗湿性年龄相关性黄斑变性（湿性 AMD）的眼用贝伐珠单抗。
Outlook Therapeutics 正式宣布，其药物 Lytenava™ 已获得美国食品药品监督管理局（FDA）批准。这是首款、也是唯一一款获 FDA 许可、专用于治疗湿性年龄相关性黄斑变性（湿性 AMD）的眼用贝伐珠单抗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.